Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507)